Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Company Overview

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Key Stats

• Today's Range: $5.03 to $5.78
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 37,920 shs
• Average Volume: 57,512 shs
• Market Capitalization: $55.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Elicio Therapeutics Stock Analysis - MarketRank™

Elicio Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 779th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Elicio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Elicio Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Elicio Therapeutics are expected to grow in the coming year, from ($3.89) to ($3.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elicio Therapeutics is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elicio Therapeutics is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Elicio Therapeutics has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.95% of the float of Elicio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Elicio Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elicio Therapeutics has recently decreased by 3.13%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elicio Therapeutics does not currently pay a dividend.

Dividend Growth

Elicio Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.95% of the float of Elicio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Elicio Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elicio Therapeutics has recently decreased by 3.13%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Elicio Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.65% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 35.03% of the stock of Elicio Therapeutics is held by institutions.

ELTX Stock Analysis - Frequently Asked Questions

How were Elicio Therapeutics' earnings last quarter?

Elicio Therapeutics, Inc. (NASDAQ:ELTX) released its quarterly earnings data on Monday, March, 31st. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.08.

When did Elicio Therapeutics IPO?

Elicio Therapeutics (ELTX) raised $40 million in an initial public offering (IPO) on the week of July 26th 2021. The company issued 3,100,000 shares at $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

What other stocks do shareholders of Elicio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Atreca (BCEL), Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 3/31/2025
• Today: 4/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ELTX
• CIK: 1555192
• Web: www.angion.com
• Phone: 415-655-4899
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +94.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,190,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -555.45%
• Return on Assets: -177.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.40
• Quick Ratio: 3.40

Sales & Book Value

• Annual Sales: $2.30 million
• Price / Sales: 24.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 3.80

Miscellaneous

• Outstanding Shares: 10,790,000
• Free Float: 7,699,000
• Market Cap: $55.35 million
• Optionable: Not Optionable
• Beta: 0.77